BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2512 related articles for article (PubMed ID: 29925654)

  • 1. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.
    Rijal P; Wang BB; Tan TK; Schimanski L; Janesch P; Dong T; McCauley JW; Daniels RS; Townsend AR; Huang KA
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31748388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
    Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
    J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
    Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
    J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase.
    Schmidt R; Holznagel E; Neumann B; Alex N; Sawatsky B; Enkirch T; Pfeffermann K; Kruip C; von Messling V; Wagner R
    Vaccine; 2016 Oct; 34(44):5329-5335. PubMed ID: 27616472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
    Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
    mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
    Job ER; Schotsaert M; IbaƱez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.
    Rosu ME; Kok A; Bestebroer TM; de Meulder D; Verveer EP; Pronk MR; Dekker LJM; Luider TM; Richard M; van den Brand JMA; Fouchier RAM; Herfst S
    J Virol; 2022 Mar; 96(6):e0195921. PubMed ID: 35107371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.
    Wohlbold TJ; Nachbagauer R; Xu H; Tan GS; Hirsh A; Brokstad KA; Cox RJ; Palese P; Krammer F
    mBio; 2015 Mar; 6(2):e02556. PubMed ID: 25759506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
    Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
    Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.
    Zheng A; Sun W; Xiong X; Freyn AW; Peukes J; Strohmeier S; Nachbagauer R; Briggs JAG; Krammer F; Palese P
    J Virol; 2020 Jul; 94(16):. PubMed ID: 32493826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 126.